CCMEP™ is the only credential that designates qualified individuals as Certified CME Professionals.
Test Development in
Buy Erlotinib (Tarceva) online on NC-CME
Erlotinib (trade names include Tarceva, Erlocip, Erlonat, Zyceva) is an anti-cancer medication from protein kinase inhibitors pharmacological group. This medicine is used for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It works as an epidermal growth factor receptor inhibitor (EGFR inhibitor).
How and where to order Erlotinib (Tarceva) 150 mg tablets online:
||from $34.30 per bottle
||5% coupon: 5OFF
||Tarceva (Erlotinib) 150 mg tablets
||Tarceva generic, Erlonat brand
||Visa, MasterCard, AmEx, JCB, Bitcoin
||Unregistered Mail or Trackable Courier
||Worldwide, including USA, UK, Europe, Canada, Australia
Afatinib (Gilotrif )
Cabozantinib (Cabometyx, Cometriq)
Everolimus (Zortress, Certican)
Lapatinib (Tykerb, Tyverb)
Lenvatinib (Lenvima, Lenvanix)
Pharmacological and medical categories:
Anti cancer drugs
NSCLC treatment medications
Pancreatic cancer therapy
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XE - Protein kinase inhibitors
L01XE03 - Erlotinib
Malignant neoplasm of pancreas - C25
Malignant neoplasm of bronchus and lung - C34
Indications and usage:
Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Dosage and administration:
The dose for NSCLC is 150 mg/day.
The dose for pancreatic cancer is 100 mg/day.
All doses of Tarceva should be taken on an empty stomach at least one hour before or two hours after food.
Reduce in 50 mg decrements, when necessary.
Adverse reactions, side effects:
The most common adverse reactions (>20%) in maintenance treatment are rash-like events and diarrhea.
The most common adverse reactions (>20%) in 2nd line NSCLC are rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, infection and vomiting.
The most common adverse reactions (>20%) in pancreatic cancer are fatigue, rash, nausea, anorexia, diarrhea, abdominal pain, vomiting, weight decrease, infection, edema, pyrexia, constipation, bone pain, dyspnea, stomatitis and myalgia.
C - Australia (Risk cannot be ruled out)
N - United States (Not classified yet)
Salts and other forms:
Synonyms, international and chemical names:
Brands, generics, trade names:
Erlocip - Cipla
Erlonat - Natco Pharma
Erlotinib - Mylan
Tarceva - Roche, Genentech, OSI Pharmaceuticals, Schwarz Pharma
Zyceva - Zydus pharmaceuticals
Updated: February 2020
Reviewed: February 2020